L. Bene

发表

Partial Protection against Dextran Sodium Sulphate Induced Colitis in Histamine-Deficient, Histidine Decarboxylase Knockout Mice

A. Falus, E. Buzás, Z. Tulassay, 2004, Journal of pediatric gastroenterology and nutrition.

Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease

L. Romics, Z. Prohászka, G. Füst, 2003, Immunogenetics.

Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients

G. Veres, T. Molnár, M. Papp, 2007, Inflammatory bowel diseases.

Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.

F. Nagy, M. Papp, P. Lakatos, 2010, Journal of Crohn's & colitis.

[Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].

T. Molnár, M. Papp, P. Lakatos, 2010, Orvosi hetilap.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

K. Farkas, T. Molnár, M. Papp, 2016, Journal of Crohn's & colitis.

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study

P. Rutgeerts, D. Hommes, C. Bernstein, 2010, Inflammatory bowel diseases.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Inflammatory bowel diseases.

Elevated Levels of Anti-Helicobacter pylori Antibodies in Henoch–Schönlein Purpura

S. Sipka, Z. Szekanecz, P. Demeter, 2003, Autoimmunity.

Cellular and Molecular Mechanisms in the Two Major Forms of Inflammatory Bowel Disease

A. Falus, A. Fulop, Noemi J. Baffy, 2011, Pathology & Oncology Research.

Raft and cytoskeleton associations of an ABC transporter: P‐glycoprotein

Z. Bacso, K. Goda, G. Szabó, 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Sensitivity of Helicobacter pylori detection by Giemsa staining is poor in comparison with immunohistochemistry and fluorescent in situ hybridization and strongly depends on inflammatory activity

M. Werner, Á. Csanádi, A. Kiss, 2017, Helicobacter.

High Normal Serum Levels of C3 and C1 Inhibitor, Two Acute-Phase Proteins Belonging to the Complement System, Occur More Frequently in Patients with Crohn's Disease Than Ulcerative Colitis

M. Daha, H. Farkas, Z. Prohászka, 2003, Digestive Diseases and Sciences.

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Expert opinion on drug safety.

Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

K. Farkas, T. Molnár, M. Papp, 2017 .

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort.

T. Molnár, M. Papp, P. Lakatos, 2017, Journal of Crohn's & colitis.

P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort.

F. Nagy, T. Molnár, M. Papp, 2017, Journal of Crohn's & colitis.

Impaired Humoral Immune Response Against Mycobacterial 65-kDa Heat Shock Protein (HSP65) in Patients with Inflammatory Bowel Disease

Mahavir Singh, L. Romics, Z. Prohászka, 2002, Digestive Diseases and Sciences.

Low levels of antibodies against E. coli and mycobacterial 65kDa heat shock proteins in patients with inflammatory bowel disease

L. Romics, Z. Prohászka, G. Füst, 2004, Inflammation Research.

Comparison of epitope specificity of anti-heat shock protein 60/65 IgG type antibodies in the sera of healthy subjects, patients with coronary heart disease and inflammatory bowel disease

Z. Prohászka, G. Füst, F. Hudecz, 2012, Cell Stress and Chaperones.

F. Nagy, M. Papp, P. Lakatos, 2015 .

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study

P. Rutgeerts, D. Hommes, C. Bernstein, 2010, Inflammatory bowel diseases.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

P002 SERO-REACTIVITY TO MICROBIAL COMPONENTS IN CROHN'S DISEASE IS ASSOCIATED WITH ILEAL INVOLVEMENT, NON-INFLAMMATORY DISEASE BEHAVIOUR AND NOD2/CARD15 GENOTYPE, BUT NOT RESPONSE TO MEDICAL THERAPY OR RISK FOR SURGERY

T. Molnár, M. Papp, Z. Tulassay, 2007 .